LinkedIn Profile

Access Juventas Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:juventastherapeutics 3118840 Dec 3rd, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Dec 3rd, 2020 11:09AM Dec 3rd, 2020 11:09AM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Dec 2nd, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Dec 2nd, 2020 01:30PM Dec 2nd, 2020 01:30PM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Dec 1st, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Dec 1st, 2020 01:06PM Dec 1st, 2020 01:06PM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Nov 30th, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Nov 29th, 2020 07:11PM Nov 30th, 2020 01:57PM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Nov 28th, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Nov 28th, 2020 02:46PM Nov 28th, 2020 02:46PM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Nov 27th, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Nov 27th, 2020 11:11AM Nov 27th, 2020 11:11AM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Nov 26th, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Nov 26th, 2020 12:09PM Nov 26th, 2020 12:09PM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Nov 25th, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Nov 25th, 2020 05:28PM Nov 25th, 2020 05:28PM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Nov 24th, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Nov 24th, 2020 12:40PM Nov 24th, 2020 12:40PM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services
private:juventastherapeutics 3118840 Nov 23rd, 2020 12:00AM Juventas Therapeutics, Inc. 353 5.00 Open Biotechnology Nov 23rd, 2020 02:46PM Nov 23rd, 2020 02:46PM Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease. Open Cardiovascular Therapeutics, Non-viral Gene Therapy, Clinical Trials, Regenerative Medicine Open 3615 Superior Avenue, Suite 4403B Cleveland Ohio US 44114 Juventas Therapeutics Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.